Reliable detection and differentiation of HR HPV (and LR HPV) genotypes by multiplex real-time PCR.
Human papillomavirus (HPV) infection is the most common sexually transmitted infections globally. The link between persistent infection and cervical cancer has lead to the emergence of cancer screening programs to better stratify women and their risk of developing cervical cancer. Over 150 HPV types have been identified where some have been implicated as major risk factors in cervical cancer. The clinical significance of persistence and clearance rates of virus over time on the severity and progression, as well as co-infection of high- and low-risk HPV types, have recently been identified as factors for disease progression. However, current HPV diagnostic tools are limited in their use for the detection, identification and differentiation of multiple HPV genotypes.
The GeneFirst Papilloplex® HPV tests have been designed to address these unmet medical needs by simultaneous detection and differentiation of genotypes to better stratify disease risk and progression. These tests, based on GeneFirst’s proprietary MPA technology, aids our understanding of genotype-specific HPV infection in developing strategies to enhance the prevention and management of cervical cancer.
Assay contains primers, target specific probes and their partially complementary oligonucleotides (PCO).
Each probe/PCO hybrid is designed to have a unique melting profile.
preferentially binds to the target, and the probe is consumed during amplification. This results in change in melting profile relevant to the specific target(s) in the sample.
Simultaneous detection and differentiation of all high-risk types including 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68